Brinzolamide-timolol suspension is well-tolerated in glaucoma patients

April 11, 2011

The administration of brinzolamide-timolol suspension has a minimal effect on quality of life and is generally favoured when compared with other drops, according to a study published in Clinical Ophthalmology.

The administration of brinzolamide-timolol suspension has a minimal effect on quality of life and is generally favoured when compared with other drops, according to a study published in Clinical Ophthalmology.

Dr M. Doherty et al., Sunderland Eye Infirmary, Sunderland, Tyne and Wear, distributed a questionnaire to 76 patients listed under the Sunderland Eye Infirmary Glaucoma Service who were administered the brinzolamide-timolol suspension. The questions involved effects on daily life, visiual blurring, stinging, irritation and acceptability to the topical ocular antihypertensive preparation. Answers were ranked using a numerical scale from 0 to 10.

All patients participated and included 58 females and 18 males all aged between 68–95 years. The treatment ranged from 3 to 7 months.It was found that the patient's quality of life was hardly affected with a rating between 0 and 2. Stinging and irritation were also low scoring in the responses but visual blurring was rated a little higher, at 3 on average. Addiotionally, the majority of respondents preferred brinzolamide-timolol suspension over other topical medications.

The findings demonstrate that brinzolamide-timolol suspension is an acceptable medication with few side effects.